Should risk-adapted MM treatment be informed by age or frailty status?
Multiple Myeloma Hub
by Scientific Education Support
9M ago
The Multiple Myeloma Hub was pleased to speak to Hira Mian, McMaster University, Hamilton, CA. We asked, Should risk-adapted MM treatment be informed by age or frailty status? In this podcast, Hira Mian discusses the relationship between age and frailty status, sharing her perspective on how they may inform treatment strategies for patients with multiple myeloma. Mian examines the influence of age on frailty status, but notes other influential factors featured in the International Myeloma Working Group (IMWG) frailty score. Mian concludes with the importance of a comprehensive frailty assessme ..read more
Visit website
What are the main discrepancies between MM treating centers in Brazil?
Multiple Myeloma Hub
by Scientific Education Support
1y ago
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Vania Tietsche de Moraes Hungria, Clínica São Germano, São Paulo, BR. We asked, What are the main discrepancies between multiple myeloma (MM) treating centers in Brazil? In this podcast, Hungria discusses their poster presented at ASH 2022 entitled: A Brazilian real-life experience of multiple myeloma patients: Final results from the Mmybrave multi-center study. In particular, Hungria discusses the setting of this research, looking at the differences in the char ..read more
Visit website
What are the initial data of dara-CyBorD in patients with extramedullary disease?
Multiple Myeloma Hub
by Scientific Education Support
1y ago
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub was pleased to speak to Meral Beksac, Ankara University, Ankara, TR. We asked, What are the initial data of dara-CyBorD in patients with extramedullary disease? In this podcast, Beksac discusses their poster presented at ASH 2022 entitled: Efficacy of daratumumab combined with bortezomib, cyclophosphamide and dexamethasone for the treatment of multiple myeloma patients presenting with extramedullary disease: a European Myeloma Network study. Beksac outlines the methods and motivations ..read more
Visit website
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting?
Multiple Myeloma Hub
by Scientific Education Support
1y ago
During the 19th International Myeloma Society Annual Meeting, the Multiple Myeloma Hub was pleased to speak to Roman Hájek, University of Ostrava, Ostrava, CZ. We asked, Which patients might benefit the most from isatuximab-based combinations in the relapsed setting? Hájek begins by explaining that isatuximab is an anti-CD38 monoclonal antibody currently approved for treatment in combination with pomalidomide + dexamethasone or carfilzomib + dexamethasone. This is followed by a discussion on why these combinations may be helpful for patients previously exposed or refractory to lenalidomide ..read more
Visit website
What are the pros and cons of bispecific antibodies for multiple myeloma?
Multiple Myeloma Hub
by Scientific Education Support
2y ago
During the ASCO 2022 Congress, the Multiple Myeloma Hub was pleased to speak to Roberto Mina, University of Turin, Turin, IT, and Andrzej J. Jakubowiak, The University of Chicago, Chicago, US. We asked, What are the pros and cons of bispecific antibodies for multiple myeloma?  Mina and Jakubowiak discuss the MajesTEC-1 and MagnetisMM-1 trials, the efficacy and response rates of bispecific antibodies, and the challenges of using bispecific antibodies, such as infection risk. They also compare bispecific antibodies to CAR T-cell therapies and talk about the sequencing of therapies in myelo ..read more
Visit website
Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM
Multiple Myeloma Hub
by Scientific Education Support
2y ago
During the 3rd European Myeloma Network Meeting, the Multiple Myeloma Hub was pleased to speak with María-Victoria Mateos, University Hospital of Salamanca, Salamanca, ES. We asked, How can bispecific antibodies be combined with monoclonal antibodies to treat relapsed/refractory multiple myeloma? Mateos begins by giving an overview of the bispecific antibodies, talquetamab and teclistamab. These antibodies have been investigated in combination with daratumumab in two clinical trials; Mateos provides a summary of the results of these trials, including the safety and efficacy data. See acast.c ..read more
Visit website
Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM
Multiple Myeloma Hub
by Scientific Education Support
2y ago
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Michel Delforge, UCLouvain, Louvain-la-Neuve, BE and Noopur Raje, Massachusetts General Hospital, Boston, US. In this podcast, they discuss the topic: Managing infections with novel immunotherapies: Prevention, treatment, and impact on the quality of life of patients with multiple myeloma. Raje and Delforge discuss the management of infections with novel immunotherapies, including: monoclonal antibodies, antivirals, risk ..read more
Visit website
Should 'cure' be the goal for multiple myeloma?
Multiple Myeloma Hub
by Scientific Education Support
2y ago
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? This podcast captures the roundtable discussion with Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University (Paris, FR), María-Victoria Mateos, University Hospital of Salamanca (Salamanca, ES), and Sagar Lonial, Winship Cancer Institute of Emory University (Atlanta, US), and includes the concluding remarks of the Satellite Symposium as a whole. See acast.com/privacy for privacy and opt-out information ..read more
Visit website
Treating elderly and frail patients with MM: Cure versus disease control
Multiple Myeloma Hub
by Scientific Education Support
2y ago
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Vincent Rajkumar, Mayo Clinic, Rochester, US, discussed: Treating elderly and frail patients with MM: Cure versus disease control. In this podcast, Rajkumar discusses the current standard of treatment for elderly, frail patients (VRd−bortezomib, lenalidomide, dexamethasone) and regimens that are currently being tested across various clinical trials to improve upon this standard, such as replacement o ..read more
Visit website
Is transplantation still relevant? If yes, in what context?
Multiple Myeloma Hub
by Scientific Education Support
2y ago
During the 7th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub hosted its first Satellite Symposium: Should 'cure' be the goal for multiple myeloma? Sagar Lonial, Winship Cancer Institute of Emory University, Atlanta, US, answered: Is transplantation still relevant? If yes, in which context? In this podcast, Lonial describes results from the FORTE (NCT02203643) and IFM 2009 (NCT01191060) trials, which investigated the use of triplet combinations with and without transplant. He warns of the 'siren song' of early MRD negativity that may lead one to believe n ..read more
Visit website

Follow Multiple Myeloma Hub on FeedSpot

Continue with Google
Continue with Apple
OR